663-amino acid heavy subunit of the transporter is defecin two patients and on Type II alleles in two patients. These retive in cystinuria [2] . Over 40 mutations have been results suggest that Type II and Type III may be caused by the same mutation and, therefore, other factors must influence uriported in this gene [8] . Heterozygotes, with presumably nary cystine excretion. A 4bp deletion in intron 12 (IVS12ϩ4-50% of SLC3A1 function, excrete cystine in the normal delAGTA) and a missense mutation (1245G→A, A354T) were range [9] . identified on Type III alleles. A nonsense codon (1491G→T, Three types of cystinuria have been described, based on E436X) and a possible splicing mutation (IVS9-17G→A) were seen in a Type I/III patient, but the mutations could not be asthe level of urinary cystine in obligate heterozygotes. Type signed to particular alleles. Of additional interest were two I/N heterozygotes excrete cystine at normal levels (0 to missense mutations (316T→C, I44T and 967C→T, P261L) linked 100 mol cystine/g creatinine), whereas Type II/N and to Type I alleles.
Type III/N heterozygotes exhibit high or moderate exConclusion. Our results provide evidence that some SLC7A9 mutations may be associated with fully recessive (Type I) forms cretion (Ͼ900 or 100 to 900 mol cystine/g creatinine), of cystinuria. We also demonstrate SLC7A9 mutations in domirespectively [10] . Only in Type II/N heterozygotes is the nant Types II and III cystinuria. The finding of SLC7A9 mutacystine excretion high enough to put them at risk for tions in all three subtypes underscores the complex interactions stone formation. Offspring who inherit two mutant cystibetween specific cystinuria genes and other factors influencing cystine excretion. A simpler phenotypic classification scheme nuria genes excrete much higher levels of cystine, often (recessive and dominant) for cystinuria is warranted.
exceeding its solubility threshold.
The three cystinuria phenotypes were initially attributed to allelic variants of the same gene but family studies suggestive of "genetic complementation" between Type I and Type III cystinuria prompted the hypothesis that Types I/III and III/III were not linked [12] . The cystinuria gene at this locus was identified as SLC3A1; all o,ϩ AT with rBAT resulted in the proper localization of the latter in the plasma memfrom Applied Biosystems (Foster City, CA, USA). brane, and in the uptake of l-arginine into COS cells;
Identification of mutations these cells are a fibroblast-like cell line established from CV-1 simian cells from kidney of the African green monWe used public genomic DNA sequence databases for the establishment of solid guidelines for SLC7A9 gene key. In contrast, transfection of rBAT alone resulted in the arrest of the expressed protein in the endoplasmic structure. High-throughput sequencing of the BAC clone CITB-HI_2085J24 by the Doe-Joint Genome Institute reticulum. The International Cystinuria Consortium identified the first mutations in the SLC7A9 gene [13] . Libyan (GenBank Accession No. AC008805) revealed relevant preliminary sequence information for design of PCR primJewish patients were homozygous for a founder missense mutation. In other patients, two frameshift mutations and ers. We independently confirmed (GenBank Accession Nos AF421170 to AF421181) the sequence of SLC7A9 four missense mutations were identified. More recently, 28 other SLC7A9 mutations in non-Type I cystinuria coding exons and their boundaries. They were analyzed as 12 segments that were subjected to polymerase chain cases were reported [14] .
The present study was undertaken to identify SLC7A9 reaction (PCR)-dependent heteroduplex and single-strand conformational polymorphism (SSCP) analysis. mutations in cystinuria patients who have been carefully classified into the three phenotypic subtypes, on the basis Single-strand conformational polymorphism (SSCP) and heteroduplex analyses were carried out as described of the excretion pattern of obligate heterozygous parents. Our analysis addresses the difficult question of gepreviously [9] . primers: sense primer of fragment I, SLC7A9E2-F2, 5Ј-TGTGCGCCCTCCTTGCAGT-3Ј; reverse primer of of obligate heterozygous parents, as previously described [10] . All these patients but one (I/I phenotype) are exfragment IV, SLC7A9E5-R2, 5Ј-TGCTTCCTTGGAGA TGGGCT-3Ј; and sense primer of fragment V, SLCpected to carry at least one dominant or semi-dominant (Type II or Type III) allele. Relevant biochemical data 7A9E6-F2, 5Ј-TCCCGTGGAGATACACTCA-3Ј. PCR products were verified by acrylamide gel electrophoresis, are presented in Table 1 for the eight patients who were shown to carry mutations in SLC7A9. We did not find allowing for potential heteroduplex formation to be visualized before undergoing SSCP. Fragments displaying any evidence for mutations in SLC7A9 in the other five patients.
shifts by SSCP or heteroduplex analysis were sequenced directly or subcloned and sequenced. Sequencing was Materials performed on both strands using the primers of the initial PCR amplification, with Sequenase kits or by fluoresOligonucleotide primers were synthesized by the Sheldon Biotechnology Center (McGill University, Montcence-based automated analysis on an ABI-310 PRISM Genetic Analyzer (Applied Biosystems). real, Canada) and ACGT (Toronto, Ontario, Canada). Taq DNA polymerase, Platinum Taq DNA polymerase Confirmation of mutations and PCRx Enhancer Solution were purchased from Life Technologies (Burlington, Ontario, Canada). Restriction
The confirmation of mutations in genomic DNA was made by PCR-dependent diagnostic tests. These tests enzymes were from New England Biolabs (Mississauga, examined the creation or destruction of a particular re-PCR was carried out using 2 L template, 250 ng each specific primer, 1 L each dNTP (from a 10 mmol/L striction site due to a specific mutation. The oligonucleotides used for diagnostic tests are listed in Table 2 . Some stock) and 3 U Taq polymerase in a 50 L volume. Digestion was carried out using 5 to 16 L of the PCR of these primers also were used for SSCP analysis (described in the previous paragraph). If the mutation did product with the appropriate restriction enzyme for 3 to 16 hours at the required temperature before subjecting not change a restriction site, one was created through the use of an oligonucleotide in which one of the 3Ј end the samples to electrophoresis on an 8% acrylamide gel. For each of the mutations resulting in a nucleotide substinucleotides was altered. This altered oligonucleotide generated an artificially-created restriction site (ACRS) tution and where the result did not lead to a stop codon, at least 50 control samples were analyzed for mutations when found in combination with a specific allele, cutting the appropriate PCR product to generate the expected to ensure that they were not common polymorphisms. fragments (ACRSDdeI: 5Ј-GCTTCATTACAGGAAA Computer analysis of splicing mutations CACTAA-3Ј, ACRSMseI: 5Ј-ATGGGCTCAGAAAA TCTCAATTA-3Ј and ACRSSduI: 5Ј-TTGGCCATTA Computer analysis of the strength of splice sites of ge-TCATCGGGAGCC-3Ј). Underlined letters indicate the nomic sequences spanning relevant nucleotides was pernucleotides that were altered to create a new restriction formed using programs from the Individual Information site in combination with downstream sequence. The primer package of Schneider [15] . Programs used included deMnlIsense 5Ј-GTCTCCGTGTCATTGCCTCTC-3Ј was lila, scan, exon, and lister. These are a few of the memdesigned to avoid the interference of other MnlI segbers of the large Delila package [16] (from the Laboratory of Computational and Experimental Biology at the ments in the diagnostic assays. Primers SLC7A9E5-R3: 5Ј-GGTGAAGATGTTCTGGACGTA-3Ј and ACRSNational Institutes of Health, http://www.lecb.ncifcrf.gov/ ϳtoms/). Scan calculates the strengths of splice donor and BstUI 5Ј-CTGGCCCAAGGTGACCCGC-3Ј were used to confirm variants that were observed in cystinuria paacceptor sites, and lister displays the results. Values of the Individual Information variable R i (b, l, j) tients as well as in normal controls (Table 3) . Genomic a These mutations were absent from panels of normal controls b Cystinuria patients that are positive for these mutations are listed in Table 1 c Sense/antisense primers used for PCR; sequences or relevant citation are given in the Methods section d Size of undigested PCR product for normal allele e Expected sizes of cleavage products for homozygotes. Heterozygotes will contain a mixture of normal and mutant patterns. f Refers to panels in Figure 1 g Diagnostic test designed for identification and confirmation of the mutation h Assay performed for testing the absence of this mutation in normal DNA samples are calculated for each base and position of the selected RESULTS sequence, j, in the range of interest. In this situation, Table 1 summarizes the phenotypes and SLC7A9 mu-R i (b, l, j) is the difference in uncertainty before and after tations of patients and available parents. Table 2 probinding of a specific base, b, at a specific position, l, relavides the details of the diagnostic procedures used to tive to the origin of an acceptor or donor sequence, j. In this child, a heteroduplex pattern in segment XI trate the Individual R i contributions of the bases to the (370 bp) was found to be due to a deletion of 4 bp in inacceptor or donor site at a location. On these plots, bases tron 12, IVS12ϩ4delAGTA (Fig. 1A) . The deletion was that contribute positively to the R i sum point upward, characterized by sequencing independent subclones genthose that contribute negatively point down. The height erated from PCR products that yielded the heteroduplex of the letter is proportional to the information contribupattern. The mutation was confirmed using a ACRStion of that base. The R i sum is given along with the based MseI diagnostic test where 21 bp are removed type of site for which it is calculated. The programs were from the 96 bp normal allele after digestion, leaving the run on a Sun SPARCstation 2 under Sun OS 5.5.
92 bp mutant amplicon undigested (data not shown also heterozygous for this mutation while his father (GH, to a splicing defect. According to the information theory model, the mutation is predicted to abolish splicing 1940-01) is negative (Fig. 1A) . Therefore this mutation is associated with the Type III phenotype. The second (Fig. 2C) since the R i value is inferior to the threshold of 2.4 bits [17] . mutation in this patient has not yet been identified.
The four deleted bases can be seen as one unit of a Patient AW (872-01, Type I/III) direct repeat of four bases ( Fig. 2A) . This mutation results in a modification of the context surrounding the
In this child, an extra band was detected through SSCP natural 5Ј splice site. Comparison with Senapathy's comanalysis of segment XI, which encompasses exon 12. This pilations (Fig. 2B) , as well as Neural Network analysis extra band proved to be caused by a nonsense mutation, 1491G→T (E436X), which should result in the trunca- (Fig. 2C ), suggests that IVS12ϩ4delAGTA should lead . Splice sites sequences are shown by sequence walkers, in which the height of each letter is the contribution of that base to the total information of the site (in bits) [16] . The upper boundary of the vertical rectangles is at ϩ2 bits, and the lower boundary is at Ϫ3 bits. Letters that are upside down represent negative contributions. The top walker diagram depicts the natural splice site and the lower one corresponds to the mutated sequence. The deletion substantially lowers the R i value of the donor site, making it non-functional [17].
tion of 52 amino acids at the C-terminal; this region ever, we cannot exclude the possibility that this change has a more severe impact than predicted, since it is loincludes the last putative transmembrane domain and the C-terminus of b o,ϩ AT [13] . The mutation creates a cated within a long polypyrimidine tract, between the branchpoint sequence and the acceptor site (Fig. 3) . For single SexAI site not present in the normal sequence (Fig. 1B) . The patient is heterozygous for this mutation.
example, it could lead to an alteration of secondary structure that interferes with the splicing machinery, or it An additional band in the SSCP pattern for segment could have an influence on a splicing enhancer. These IX of the same patient (AW) proved to be caused by types of effects would be compatible with the mild defect another point mutation, IVS9-17G→A, also in the hetexpected for a Type I allele of a Type I/III proband. erozygous state in the patient. This mutation, identified through direct sequencing of the PCR product, is located Patients DR (918-01, Type II/N), KD (1875-01, in an intronic segment containing elements that influence Type III/III), MS (1245-03, Type I/II) and splicing (Fig. 3) . The mutation creates a second NlaIII PD (1390-01, Type I/III) site in the 210 bp genomic segment (Fig. 1C) . Because the father has British ancestors, we verified the absence In these patients, a band was observed on SSCP gels of amplified segment V. After subcloning the PCR prodof the mutation in a panel of 50 British controls in addition to our standard set of 51 controls from Quebec (data uct, it was found to contain an insertion of one bp in exon 6 between nucleotides 799/800 of the cDNA senot shown). The Scan program predicts a slight decrease in the information content of the acceptor site for mutaquence, adding an extra adenosine to a stretch of three consecutive adenosines (data not shown). It is predicted tion IVS9-17G→A, which is not predicted to have a significant effect on splicing (data not shown). The mutato change the reading frame of the cDNA, creating a downstream termination signal. The mutation was contion does not create new donor or acceptor sites. How- firmed using a modified sense primer, by testing for the presence of a DdeI restriction site specific to the normal 177 bp genomic segment (Fig. 1D) . The mutation was found to be heterozygous in all four patients. For MS (1245-03) and PD (1390-01), we showed that the frameshift mutation was transmitted to the probands by the mother and the father, who have Type II and Type III phenotypes, respectively (data not shown).
Patient MS (1245-03, Type I/II)
In this patient, a second mutation was seen as an extra band during SSCP analysis of segment VII. DNA sequencing revealed that the extra band was caused by the point mutation 967C→T (P261L), which creates a MnlI site. However, we could not use the SSCP primers to perform a MnlI-diagnostic test, because MnlI digestion of the SSCP fragment generates bands that interfere with the same change (Fig. 1E) , which was absent in a set of 50 British controls as well as the 51 Quebec controls. Although the MnlI diagnostic assay was useful for confirming the mutation, it was technically difficult, requirpoint mutation, 316T→C (I44T), identified through diing radioactive PCR products to achieve the required rect sequencing of the amplified segment. This mutation sensitivity. For these reasons, the mutation 967C→T also creates a second TspRI site in the 238 bp DNA segment was confirmed through another diagnostic test (ACRS- (Fig. 1H) . The patient's father (CH, 1898-02, I/N) was based), which takes advantage of the loss of one of the positive for the same mutation (data not shown). The two SduI sites in the mutant PCR segment (Table 2 and maternal mutation is unknown. The I44T mutation was Fig. 1F ). The isoschyzomer Bsp1286I was used also and not observed in our panel of controls. showed the same results (data not shown).
Patient CL (988-01, III/N)
DISCUSSION Here, an extra band was detected during SSCP analysis For clinical purposes, the classification of cystinuria of segment IX. The band was due to an exon 10 missense has been based on urinary phenotype that presumably mutation, 1245G→A (A354T), found by direct sequencreflects the severity of the proximal tubular transport ing of PCR products (not shown). The mutation was condefect. More specifically, the urinary cystine levels of firmed through an AciI-based test (Table 2 and Fig. 1G ).
obligate heterozygous parents have been used to distin-CL proved to be heterozygous for this mutation (AciI guish three subtypes [11] . Initially, it was postulated that digestion and sequencing data, not shown).
the variations among the Types I, III and II cystinuria Patient DH (1898-03, Type I/I) subtypes might be explained by mild, moderate or severe mutations at a single locus. However, the identificaIn this child, an extra band was discovered during SSCP analysis of segment II. The band was caused by a tion of multiple mutations in two genes-SLC3A1 and SLC7A9-and the potential candidature of a third cyshad also been identified in non-Type I patients by the International Consortium. The quantitative information tinuria-causing gene, SLC7A10 [21] , indicate that the genetics is more complex than originally anticipated.
analysis, summarized in Figure 2 , predicts that the intronic change is likely to abolish splicing. The A354T Mutations in SLC3A1 thus far have been associated only with Type I alleles, primarily in patients with classimutation had been expressed by the aforementioned group and shown to abolish cystine transport. The E436X cal Type I/I cystinuria that displays autosomal recessive inheritance (normal excretion pattern in the obligate mutation, a nonsense mutation in a Type I/III proband, is likely to be quite severe, but it could not be assigned heterozygous parents). The International Cystinuria Consortium recently isolated the SLC7A9 gene and identito a phenotype since parental DNA was not available. We suggest, however, that it might be linked to the fied mutations in this gene only in non-Type I cystinuria patients. Our study of SLC7A9 mutations is consistent Type III allele, since the SLC7A9 mutations on a Type I (silent) recessive allele may be milder than those associwith a major role for this gene in non-Type I cystinuria, but also suggests that SLC7A9 mutations may account ated with the dominant Type III allele (discussed later in this article). for some Type I alleles of mixed phenotype probands (Type I/non-Type I) and of non-classic Type I/I probands.
In an earlier study of cystinuria, we examined our patients for mutations in SLC3A1. We found that mutaTaken together, these results suggest that SLC7A9 mutations cause a wide spectrum of urinary cystine levels.
tions in SLC3A1 accounted for virtually all the mutations in nine classical Type I/I patients with autosomal recesWe identified one specific mutation, 799insA, in heterozygotes of two families exhibiting a dominant pattern sive inheritance [9] , which is characterized by very high cystine excretion (range 2578 to 5778 mol cystine/g creof cystine excretion in the stone-forming (Type II/N) range, and in two families with a dominant pattern of atinine [10] ). In the mixed phenotype patients (Types I/ III), our mutation detection rate for SLC3A1 was considmoderate (Type III/N) cystinuria. This SLC7A9 frameshift should lead to premature termination of translation, erably lower, prompting us to suggest that some Type I mutations might occur in genes other than SLC3A1. In a finding that is consistent with a non-functional polypeptide. Since the same null mutation may cause either modthe current study, we identified SLC7A9 mutations in two patients with mixed phenotypes (Type I/non-Type I) erate or severe cystinuria in different families, factors other than the SLC7A9 mutation clearly influence the and in one patient with Type I/I cystinuria; two of these mutations are clearly linked to the Type I allele while level of cystine excretion. Similar conclusions were reported by the International Cystinuria Consortium [14] . one mutation could not be phased. The International Cystinuria Consortium also has recently identified SLC7A9 Nephrolithiasis, the secondary consequence of cystinuria, involves an additional level of inter-individual mutations linked to the Type I allele (M. Palacin, member of Consortium, unpublished results). variability. Thus far, all known SLC3A1 mutations exhibit a recessive urinary phenotype, yet Schmidt et al
In the Type I/I proband (DH; 1898-03), we identified the I44T missense mutation which was inherited from reported sibs with identical homozygous SLC3A1 mutations whose first stones appeared at ages ranging from 9 his father, a Type I (silent) carrier. This mutation was not present in a large series of controls. The isoleucine to 22 years [abstract; Schmidt et al, Am J Hum Genet 69(Suppl): 474, 2001 ]. Although cystinuria genes may be codon is completely conserved among members of the family of light subunits of heteromeric amino acid transpowerful determinants of the cystine excretion level, the risk of nephrolithiasis also may depend on modifiers of porters (alignment shown in [13]) as well as in the protein product of the recently identified SLC7A10 gene, ancystine precipitation or microcrystal aggregation at the tubular wall.
other potential candidate gene for cystinura (alignment in [21] ). Although expression studies should be perDuring the course of our work, the International Cystinuria Consortium described a frequent mutation (which formed to confirm the deleterious nature of the substitution, the data thus far suggest that the mutation is not they designated as c.800-801insA) in non-Type I patients, resulting from insertion of an adenosine at the neigha benign polymorphism. A putative splicing mutation in SLC7A10, which is homologous to SLC7A9 and is loboring base [14] . Our DdeI diagnostic test confirms that the extra adenosine found in our patients is present after cated within the same chromosomal region, was also identified in this patient; it had been inherited from his position 799 and not after position 800. Whether these two mutations are identical remains to be determined.
father (proband number is 1869-1 in [21] ). As discussed in that study, two mutations might be required to exhibit Three of the other identified SLC7A9 mutations in our patients also are likely to have severe consequences: a phenotype. Relevant to this finding is the observation that SLC7A9 mutations A354T and A182T were found the IVS12ϩ4delAGTA splicing mutation, the A354T missense mutation, and the E436X nonsense mutation. on a single allele by the International Consortium with negligible and partial transport activity, respectively [14] . The splicing and missense mutations are clearly linked to a Type III phenotype in our families; these two mutations This Type I/I proband (DH; 1898-03) has a much lower level of cystine excretion (average, 1013 mol cystine/g genes. These patients may harbor promoter mutations, creatinine) compared to the aforementioned level usuintronic changes creating or enhancing cryptic splice ally seen in classic Type I/I probands with homozygous sites, as well as large genomic rearrangements in either mutations of SLC3A1. A mutation in SLC7A9, instead of the known cystinuria genes. However, the involveof SLC3A1, may be associated with a milder phenotype ment of a third gene is a distinct possibility. SLC7A10 in Type I/I patients.
mutations have been reported [21] but other genes are The other SLC7A9 change observed on Type I allele likely to be identified. The recent review by Chillaron is a P261L mutation observed in a father [Type I (silent) et al discusses the opposite gradients of expression obcarrier] and in his cystinuric son (patient MS; 1245-03).
served for b o,ϩ AT and rBAT along the kidney proximal Again, this mutation was not observed in a large panel tubule, and promotes the hypothesis of additional genes of controls and the residue is conserved to the same [22] . Careful biochemical characterization of patients extent as described above for the I44T change. In addiand their families, combined with molecular biologic tion, because proline is an imino acid, substitution of studies, should continue to clarify the complex genetics a proline is believed to be deleterious because of the of this transport disorder. secondary rather than a primary amino group. Presumably the P261L mutation is relatively mild since the het-NOTE ADDED IN PROOF erozygous father excretes cystine in the normal range and the proband (who also inherited the dominant The mutation reported by the International Cystinuria 799insA frameshift mutation from his mother) excretes Consortium as c.800-801insA was in fact c.799-800insA. cystine in the range of his mother and maternal grandfaConsequently, it is the same mutation (799insA) as that ther who have only the 799insA change (Fig. 4) .
identified in this report (communicated by M. Palacin, The intronic change, IVS9-17G→A, was observed in International Cystinuria Consortium). patient AW (#872-01; Type I/III) who also carried the E436X nonsense mutation; these mutations could not ACKNOWLEDGMENTS be assigned to particular alleles. However, if the other
